XOMA Co. (NASDAQ:XOMA) Major Shareholder Bvf Partners L. P/Il Sells 500,742 Shares

XOMA Co. (NASDAQ:XOMA) major shareholder Bvf Partners L. P/Il sold 500,742 shares of the company’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $26.10, for a total transaction of $13,069,366.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

XOMA Trading Down 0.9 %

NASDAQ XOMA opened at $26.26 on Friday. XOMA Co. has a 52 week low of $19.50 and a 52 week high of $35.00. The firm has a 50 day moving average of $27.91 and a two-hundred day moving average of $28.09. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. The stock has a market capitalization of $309.34 million, a PE ratio of -7.55 and a beta of 0.92.

XOMA (NASDAQ:XOMA) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.05. The business had revenue of $7.20 million for the quarter, compared to analyst estimates of $6.66 million. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. As a group, research analysts expect that XOMA Co. will post -1.41 EPS for the current fiscal year.

Hedge Funds Weigh In On XOMA

Hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets raised its holdings in shares of XOMA by 95.0% in the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 795 shares during the last quarter. Rhumbline Advisers increased its position in XOMA by 18.1% in the 4th quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company’s stock valued at $291,000 after acquiring an additional 1,699 shares during the period. Barclays PLC raised its stake in XOMA by 300.7% during the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after acquiring an additional 8,447 shares during the last quarter. Ellsworth Advisors LLC acquired a new stake in XOMA during the 3rd quarter worth approximately $516,000. Finally, State Street Corp lifted its position in XOMA by 1.2% during the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock worth $3,783,000 after acquiring an additional 1,754 shares during the period. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on XOMA. StockNews.com raised XOMA from a “sell” rating to a “hold” rating in a research report on Thursday, January 16th. HC Wainwright reissued a “buy” rating and set a $123.00 target price on shares of XOMA in a research note on Tuesday, January 7th.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.